CN102947269B - 噻唑烷二酮化合物的新的合成方法 - Google Patents

噻唑烷二酮化合物的新的合成方法 Download PDF

Info

Publication number
CN102947269B
CN102947269B CN201180030253.8A CN201180030253A CN102947269B CN 102947269 B CN102947269 B CN 102947269B CN 201180030253 A CN201180030253 A CN 201180030253A CN 102947269 B CN102947269 B CN 102947269B
Authority
CN
China
Prior art keywords
group
alkyl
formula
compound
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180030253.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102947269A (zh
Inventor
J.R.泽勒
S.P.坦尼斯
S.D.拉森
T.帕克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siri Maher J Therapy Ltd By Share Ltd
Original Assignee
Metabolic Solutions Development Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Development Co LLC filed Critical Metabolic Solutions Development Co LLC
Publication of CN102947269A publication Critical patent/CN102947269A/zh
Application granted granted Critical
Publication of CN102947269B publication Critical patent/CN102947269B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/51—Acetal radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1896—Compounds having one or more Si-O-acyl linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CN201180030253.8A 2010-04-19 2011-04-18 噻唑烷二酮化合物的新的合成方法 Expired - Fee Related CN102947269B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32550210P 2010-04-19 2010-04-19
US61/325,502 2010-04-19
US32749810P 2010-04-23 2010-04-23
US61/327,498 2010-04-23
PCT/US2011/032822 WO2011133442A1 (en) 2010-04-19 2011-04-18 Novel synthesis for thiazolidinedione compounds

Publications (2)

Publication Number Publication Date
CN102947269A CN102947269A (zh) 2013-02-27
CN102947269B true CN102947269B (zh) 2015-11-25

Family

ID=44148625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180030253.8A Expired - Fee Related CN102947269B (zh) 2010-04-19 2011-04-18 噻唑烷二酮化合物的新的合成方法

Country Status (15)

Country Link
US (1) US8937182B2 (enExample)
EP (1) EP2560956B1 (enExample)
JP (1) JP2013525355A (enExample)
KR (1) KR101781665B1 (enExample)
CN (1) CN102947269B (enExample)
AU (1) AU2011242956B2 (enExample)
CA (1) CA2796437C (enExample)
DK (1) DK2560956T3 (enExample)
ES (1) ES2610623T3 (enExample)
HU (1) HUE030263T2 (enExample)
MX (1) MX2012012092A (enExample)
NZ (1) NZ602883A (enExample)
PL (1) PL2560956T3 (enExample)
RU (1) RU2012148908A (enExample)
WO (1) WO2011133442A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CA2807815C (en) 2010-08-10 2018-10-02 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
US8933240B2 (en) 2010-08-10 2015-01-13 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US20210038566A1 (en) 2018-02-08 2021-02-11 Enyo Pharma Use of modulators of neet proteins for the treatment of infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0549365A1 (en) * 1991-12-26 1993-06-30 Sankyo Company Limited Thiazolidine compounds, their preparation and their therapeutic uses
WO1999035130A1 (en) * 1998-01-05 1999-07-15 Pfizer Pharmaceuticals Inc. 2,3-substituted indole compounds as cox-2 inhibitors
WO2003029251A1 (en) * 2001-09-28 2003-04-10 Biocon Limited Novel process for the synthesis of thiazolidinedione derivatives
WO2008118327A1 (en) * 2007-03-23 2008-10-02 University Of Toledo Conformationally restrained epothilone analogues as anti-leukemic agents
WO2009148195A1 (en) * 2008-06-02 2009-12-10 Daebong Ls, Ltd. 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
US5143930A (en) 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
ATE202352T1 (de) * 1991-04-11 2001-07-15 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
JPH07188227A (ja) * 1993-12-24 1995-07-25 Japan Tobacco Inc チアゾリジン誘導体及びオキサゾール誘導体
SE9702305D0 (sv) 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
US7407978B2 (en) 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6768008B2 (en) * 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
FR2817144B1 (fr) 2000-11-29 2003-01-03 Micro Mega Sa Sequence d'instruments canalaires pour l'execution d'un protocole operatoire d'endodontie
FR2861069B1 (fr) 2003-10-17 2005-12-09 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS RARs, UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
JP2009530293A (ja) 2006-03-16 2009-08-27 メタボリック ソリューションズ ディベロップメント カンパニー チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法
EP2001469B1 (en) * 2006-03-16 2012-05-23 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
EP2486926A1 (en) 2006-03-16 2012-08-15 Metabolic Solutions Development Company LLC Thiazolidinedione Analogues
EP2098517B1 (en) * 2006-12-01 2013-12-18 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
AU2008301905B2 (en) 2007-09-14 2013-06-27 Cirius Therapeutics, Inc. Thiazolidinedione analogues for the treatment of hypertension
MX2012012094A (es) 2010-04-19 2012-12-17 Metabolic Solutions Dev Co Llc Sintesis novedosa para compuestos de tiazolidinadiona.
CA2807815C (en) 2010-08-10 2018-10-02 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
US8933240B2 (en) 2010-08-10 2015-01-13 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0549365A1 (en) * 1991-12-26 1993-06-30 Sankyo Company Limited Thiazolidine compounds, their preparation and their therapeutic uses
WO1999035130A1 (en) * 1998-01-05 1999-07-15 Pfizer Pharmaceuticals Inc. 2,3-substituted indole compounds as cox-2 inhibitors
WO2003029251A1 (en) * 2001-09-28 2003-04-10 Biocon Limited Novel process for the synthesis of thiazolidinedione derivatives
WO2008118327A1 (en) * 2007-03-23 2008-10-02 University Of Toledo Conformationally restrained epothilone analogues as anti-leukemic agents
WO2009148195A1 (en) * 2008-06-02 2009-12-10 Daebong Ls, Ltd. 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same

Also Published As

Publication number Publication date
US8937182B2 (en) 2015-01-20
CA2796437C (en) 2018-09-11
ES2610623T3 (es) 2017-04-28
EP2560956A1 (en) 2013-02-27
CA2796437A1 (en) 2011-10-27
CN102947269A (zh) 2013-02-27
AU2011242956A1 (en) 2012-11-01
PL2560956T3 (pl) 2017-03-31
MX2012012092A (es) 2012-12-17
AU2011242956B2 (en) 2015-01-22
WO2011133442A1 (en) 2011-10-27
HUE030263T2 (en) 2017-04-28
DK2560956T3 (en) 2017-01-23
US20130204004A1 (en) 2013-08-08
HK1178155A1 (en) 2013-09-06
RU2012148908A (ru) 2014-05-27
NZ602883A (en) 2014-09-26
JP2013525355A (ja) 2013-06-20
KR20130051945A (ko) 2013-05-21
EP2560956B1 (en) 2016-10-26
KR101781665B1 (ko) 2017-09-25

Similar Documents

Publication Publication Date Title
CN103153972A (zh) 噻唑烷二酮化合物的新的合成方法
CN102947269B (zh) 噻唑烷二酮化合物的新的合成方法
CN103153991B (zh) 噻唑烷二酮化合物的合成方法
CN103180304B (zh) 噻唑烷二酮化合物的合成方法
HK1178155B (en) Novel synthesis for thiazolidinedione compounds
HK1182099B (en) Synthesis for thiazolidinedione compounds
HK1182099A (en) Synthesis for thiazolidinedione compounds
HK1181772A (en) Novel synthesis for thiazolidinedione compounds
HK1181385A (en) Synthesis for thiazolidinedione compounds
HK1181385B (en) Synthesis for thiazolidinedione compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1178155

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1178155

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20161101

Address after: michigan

Patentee after: Octeta Therapy LLC

Address before: michigan

Patentee before: METABOLIC SOLUTIONS DEVELOPMENT CO.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: michigan

Patentee after: Siri Maher J therapy Limited by Share Ltd.

Address before: michigan

Patentee before: Octeta Therapy LLC

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

CF01 Termination of patent right due to non-payment of annual fee